Denali Therapeutics Inc. (DNLI) Tops Q4 EPS by 17c
Tweet
Share
E-mailGet Alerts DNLI Hot Sheet
Join SI Premium – FREE
Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q4 EPS of ($0.67), $0.17 better than the analyst estimate of ($0.84).
For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi upgrades Bath & Body Works to Buy with $25 price target
- Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c
- XP Inc. (XP) Tops Q2 EPS by 8c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
